紫杉醇联合顺铂治疗宫颈癌的临床疗效及对患者免疫功能的影响  

Clinical efficacy of paclitaxel combined with cisplatin in the treatment of cervical cancer and its effect on the immune function of patients

作　　者：于芳 张轶群 吴勇 YU Fang;ZHANG Yiqun;WU Yong(Department of Pharmacy,Xianyang First People’s Hospital,Xianyang 712000,Shaanxi,China;Department of Pharmacy,the Third Affiliated Hospital of Xi’an Medical University,Xi’an 710000,Shaanxi,China)

机构地区：[1]咸阳市第一人民医院药剂科,陕西咸阳712000 [2]西安医学院第三附属医院药学部,西安710000

出　　处：《癌症进展》2023年第16期1839-1842,共4页Oncology Progress

摘　　要：目的探讨紫杉醇联合顺铂治疗宫颈癌的临床疗效及对患者免疫功能的影响。方法根据治疗方法的不同将70例宫颈癌患者分为A组(n=35,给予顺铂治疗)和B组(n=35,给予紫杉醇联合顺铂治疗)。比较两组患者的近期疗效、血清肿瘤标志物[鳞状细胞癌抗原(SCCA)、脊椎蛋白2(SPON2)、肿瘤特异性生长因子(TSGF)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))及不良反应发生情况。结果B组患者的客观缓解率和疾病控制率分别为74.29%和94.29%,分别高于A组患者的48.57%和77.14%,差异均有统计学意义(P﹤0.05)。治疗后,两组患者血清SCCA、SPON2、TSGF水平均低于本组治疗前,B组患者血清SCCA、SPON2、TSGF水平均低于A组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,B组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于A组,CD8^(+)水平低于A组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论紫杉醇联合顺铂治疗宫颈癌的疗效确切,可降低血清肿瘤标志物水平,改善免疫功能,且具有一定的安全性。Objective To investigate the clinical efficacy of paclitaxel combined with cisplatin in the treatment of cervical cancer and its effect on the immune function of patients.Method A total of 70 patients with cervical cancer were divided into group A(n=35,treated with cisplatin)and group B(n=35,treated with paclitaxel combined cisplatin)according to different treatment methods.The short-term curative effect,serum tumor markers[squamous cell carcinoma antigen(SCCA),spondin 2(SPON2),tumor specific growth factor(TSGF)]levels,immune function indicators(CD3^(+),CD4^(+),CD8^(+) levels,and CD4^(+)/CD8^(+)),and the incidence of adverse events were compared between the two groups.Result The objective response rate and disease control rate of group B were 74.29% and 94.29%,which were higher than 48.57% and 77.14% of group A,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum SCCA,SPON2,and TSGF in the two groups were lower than those before the treatment,and the levels of serum SCCA,SPON2,and TSGF in group B were lower than those in group A,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+) in the two groups were higher than those before the treatment,and the levels of CD8^(+) were lower than those before the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+) in group B were higher than those in group A,and the level of CD8^(+)was lower than that in group A,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse events between the two groups(P>0.05).Conclusion Paclitaxel combined with cisplatin has a definite curative effect in the treatment of cervical cancer and could reduce the level of serum tumor markers and improve patients’immune function with certain safety.

关 键 词：紫杉醇 顺铂 宫颈癌 鳞状细胞癌抗原 脊椎蛋白2 肿瘤特异性生长因子 免疫功能 

分 类 号：R737.33[医药卫生—肿瘤]